Physician profile
Michael Bergeron
NPI 1265558308
$24,038.59
in general payments reported to CMS, 2019-2025
73 companies · $3,798 in 2025
The $3,798 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,463 · 2020: $1,401 · 2021: $3,436 · 2022: $4,210 · 2023: $3,992 · 2024: $3,739 · 2025: $3,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $500 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,847.54 |
| Long Term Medical Supply Or Device Loan | $499.98 |
| Education | $180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,153.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,100.56 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $1,237.07 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $1,163.97 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Genentech USA, INC. | $1,138.91 | 2019-2025 | Tecentriq, Polivy, Lunsumio |
| E.R. Squibb & Sons, L.L.C. | $1,104.76 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $1,096.47 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $936.75 | 2019-2025 | Ninlaro, Alunbrig, Exkivity |
| Astellas Pharma US INC | $935.54 | 2019-2025 | Xtandi, Padcev |
| Celgene Corporation | $916.97 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $909.00 | 2019-2025 | |
| Amgen INC. | $760.12 | 2019-2025 | Imdelltra (Amg757), Blincyto, Kyprolis |
| Puma Biotechnology, INC. | $726.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $620.60 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Ipsen Biopharmaceuticals, INC | $584.12 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $543.26 | 2019-2025 | |
| Lilly USA, LLC | $518.73 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $451.35 | 2021-2025 | |
| Beigene USA, INC. | $416.25 | 2020-2024 | Brukinsa |
| Eisai INC. | $369.85 | 2019-2025 | |
| Stemline Therapeutics INC. | $354.33 | 2023-2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.57 | 2019-2025 | Gilotrif |
| Exelixis INC. | $303.96 | 2019-2024 | Cabometyx |
| Gilead Sciences, INC. | $277.45 | 2021-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $246.09 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $243.17 | 2019-2025 | Libtayo |
| Incyte Corporation | $233.33 | 2019-2025 | Jakafi |
| Genmab U.S., INC. | $223.80 | 2022-2025 | Tivdak, Epkinly |
| Genentech, INC. | $215.06 | 2024 | Columvi, Lunsumio, Itovebi |
| Blueprint Medicines Corporation | $205.22 | 2020-2023 | Ayvakit |
| Abbvie INC. | $194.02 | 2019-2025 | |
| Beone Medicines USA, INC. | $189.64 | 2025 | Brukinsa |
| Sobi, INC | $160.63 | 2023-2025 | |
| Array Biopharma INC | $153.57 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $147.26 | 2019 | |
| Adc Therapeutics America, INC. | $136.88 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $125.10 | 2021-2025 | Fotivda |
| Seagen INC. | $118.13 | 2020-2023 | Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $111.67 | 2019-2021 | |
| Mirati Therapeutics, INC. | $109.55 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $95.74 | 2021-2023 | |
| Servier Pharmaceuticals LLC | $90.24 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $82.47 | 2021-2025 | Monoferric |
| Taiho Oncology, INC. | $81.60 | 2023-2025 | |
| Clovis Oncology, INC. | $75.62 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $71.81 | 2024-2025 | Clonoseq |
| Progenics Pharmaceuticals, INC. | $67.47 | 2022-2023 | Pylarify |
| Emd Serono, INC. | $66.77 | 2019-2025 | |
| Springworks Therapeutics, INC. | $56.93 | 2024-2025 | Ogsiveo |
| Stryker Corporation | $51.34 | 2023 | Spinejack, Optablate |
| Dendreon Pharmaceuticals LLC | $46.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.83 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| Tempus Ai, INC | $44.23 | 2025 | Xt Cdx |
| Foundation Medicine, INC. | $42.34 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $38.02 | 2019-2021 | |
| Cti Biopharma Corp. | $30.37 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $27.54 | 2019-2025 | Pyrukynd |
| Sirtex Medical INC | $25.55 | 2023 | Sir-Spheres Microspheres |
| Novocure INC. | $23.30 | 2024 | Optune |
| Acrotech Biopharma INC. | $22.35 | 2025 | Beleodaq |
| Global Blood Therapeutics, INC. | $20.87 | 2022 | |
| Acceleron Pharma, INC. | $20.33 | 2021 | |
| Recordati_rare_diseases_inc. | $19.89 | 2025 | Sylvant |
| Tesaro, INC. | $19.77 | 2019 | |
| Secura Bio, INC. | $17.05 | 2022 | |
| Verastem, INC. | $15.84 | 2019 | |
| Dova Pharmaceuticals | $15.81 | 2021 | |
| Coherus Oncology, INC. | $15.02 | 2025 | Loqtorzi |
| Karyopharm Therapeutics INC. | $13.99 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.80 | 2023 | Odomzo, Yonsa |
| Epizyme, INC. | $13.32 | 2021 | |
| Kyowa Kirin, INC. | $13.23 | 2020 | |
| Partner Therapeutics, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bergeron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.